Share on StockTwits

Supernus Pharmaceuticals (NASDAQ:SUPN) will issue its Q114 quarterly earnings data on Monday, May 12th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $9.94 million for the quarter.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.10. The company had revenue of $10.30 million for the quarter, compared to the consensus estimate of $7.78 million. During the same quarter in the previous year, the company posted ($0.51) earnings per share. On average, analysts expect Supernus Pharmaceuticals to post $-0.85 EPS for the current fiscal year and $0.25 EPS for the next fiscal year.

Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 7.32 on Friday. Supernus Pharmaceuticals has a one year low of $4.85 and a one year high of $10.55. The stock has a 50-day moving average of $8.41 and a 200-day moving average of $8.22. The company’s market cap is $307.8 million.

A number of analysts have recently weighed in on SUPN shares. Analysts at Jefferies Group reiterated a “hold” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday. They now have a $9.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $11.36.

Supernus Pharmaceuticals, Inc (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.